ClinicalTrials.gg
TerminatedNCT00884715Updated Sep 20, 2013

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

A Phase 1/2 interventional study of Octreotide in Carcinoid Syndrome, sponsored by Endo Pharmaceuticals. Terminated at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-09-20.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Program was terminated for business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Serotonin Syndrome with a site in United States — none open to participants now, 2 under way, 1 of them phase 3. Serotonin Syndrome · United States.

Enrollment
11th of 16
10 · median 30
Started
2009
with 2 others
Phase 1/2
Only one
of the 18
Registered
5th of 18
by date
Lead sponsor
1 of 18
Endo Pharmaceuticals

Among the 18 studies in Serotonin Syndrome with a site in United States, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2009, is the only one in phase 1/2, and was the 5th registered.

Serotonin Syndrome

35 studies on the registry are indexed under Serotonin Syndrome; 1 is open to participants now.

Browse Serotonin Syndrome studies →

Open to participants now

None of the 18 studies in Serotonin Syndrome with a site in United States is open now. The open studies under Serotonin Syndrome, anywhere →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Serotonin Syndrome with a site in United States as a file.
02

Study summary

Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.

Read the detailed description

This study will evaluate a longer acting octreotide formulation. A subcutaneous implant at 2 doses will be evaluated for pharmacodynamics, efficacy and safety for a period of 9 months.

03

Conditions studied

  • Carcinoid Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed tumor
  • documented evidence of carcinoid syndrome
  • of at least 6 months
  • previous positive octreotide scan
  • received stable doses of octreotide injections
  • performance status of 0-2 on the performance scale

Exclusion criteria

Exclusion Criteria:

  • poorly differentiated or high grade neuroendocrine tumor
  • significant cv, hepatic, renal or other disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    1 implant

    117 mg Octreotide implant

    Drug: Octreotide

  • Experimental
    2 implants

    234 mg Octreotide implant

    Drug: Octreotide

Interventions

06

What researchers measure

Primary outcomes

  1. Assess the effects of 1 or 2 implants on carcinoid syndrome symptoms of flushing and diarrhea

    Time frame: 9 months

Secondary outcomes

  1. safety and tolerability of the implants

    Time frame: 9 months

07

Study locations

3 sites
  • Iowa, Iowa 52242, United States
  • Boston, Massachusetts 02115, United States
  • Burlington, Massachusetts 01805, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2009
First posted
Apr 21, 2009
Start
Jul 2009
Primary completionActual
Nov 2011
CompletionActual
Dec 2011
Results delay requested
Sep 9, 2013
Last update
Sep 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00884715
Responsible party
Sponsor
First posted
Apr 21, 2009
Start date
Jul 2009
Primary completion
Nov 2011
Completion
Dec 2011
Last update
Sep 20, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion